ULTRAGENYX PHARMACEUTICAL INC. Equity Securities, FV-NI, Gain (Loss)
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Equity Securities, FV-NI, Gain (Loss) of $678.00 thousand for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-05.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiGainLoss · last filed 2025-11-05
- ULTRAGENYX PHARMACEUTICAL INC. equity securities, fv-ni, gain (loss) for the quarter ending 2025-09-30 was $678.00K, a 0.00% change year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. equity securities, fv-ni, gain (loss) for the quarter ending 2025-06-30 was -$9.00K.
- ULTRAGENYX PHARMACEUTICAL INC. equity securities, fv-ni, gain (loss) for the quarter ending 2025-03-31 was -$157.00K, a 104.19% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. equity securities, fv-ni, gain (loss) for the quarter ending 2024-12-31 was -$1.55M, a 181.95% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. equity securities, fv-ni, gain (loss) for fiscal 2024 was -$1.11M, a 380.86% decline from fiscal 2023.
- ULTRAGENYX PHARMACEUTICAL INC. equity securities, fv-ni, gain (loss) for fiscal 2023 was $397.00K.
- ULTRAGENYX PHARMACEUTICAL INC. equity securities, fv-ni, gain (loss) for fiscal 2022 was -$19.30M.
- ULTRAGENYX PHARMACEUTICAL INC. equity securities, fv-ni, gain (loss) for fiscal 2021 was -$42.06M, a 124.68% decline from fiscal 2020.
| Period end | Equity Securities, FV-NI, Gain (Loss) 3 month | Equity Securities, FV-NI, Gain (Loss) 6 month | Equity Securities, FV-NI, Gain (Loss) 9 month | Equity Securities, FV-NI, Gain (Loss) 12 month |
|---|---|---|---|---|
| 2025-09-30 | $678.00K 10-Q · filed 2025-11-05 | $669.00K derived: sum of 2 quarters · filed 2025-11-05 | $512.00K 10-Q · filed 2025-11-05 | -$1.04M derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | -$9.00K 10-Q · filed 2025-08-06 | -$166.00K 10-Q · filed 2025-08-06 | -$1.71M derived: sum of 3 quarters · filed 2025-08-06 | -$1.04M derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-03-31 | -$157.00K 10-Q · filed 2025-05-07 | -$1.71M derived: sum of 2 quarters · filed 2025-05-07 | -$1.03M derived: sum of 3 quarters · filed 2025-11-05 | -$5.02M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-12-31 | -$1.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | -$870.00K derived: sum of 2 quarters · filed 2025-11-05 | -$4.86M derived: sum of 3 quarters · filed 2025-11-05 | -$1.11M 10-K · filed 2025-02-19 |
| 2024-09-30 | $678.00K 10-Q · filed 2025-11-05 | -$3.31M derived: sum of 2 quarters · filed 2025-11-05 | $433.00K 10-Q · filed 2025-11-05 | $2.32M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$3.99M 10-Q · filed 2025-08-06 | -$245.00K 10-Q · filed 2025-08-06 | $1.64M derived: sum of 3 quarters · filed 2025-08-06 | $225.00K derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $3.75M 10-Q · filed 2025-05-07 | $5.63M derived: sum of 2 quarters · filed 2025-05-07 | $4.22M derived: sum of 3 quarters · filed 2025-05-07 | $4.48M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $1.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $470.00K derived: sum of 2 quarters · filed 2025-02-19 | $731.00K derived: sum of 3 quarters · filed 2025-02-19 | $397.00K 10-K · filed 2025-02-19 |
| 2023-09-30 | -$1.42M 10-Q · filed 2024-11-06 | -$1.16M derived: sum of 2 quarters · filed 2024-11-06 | -$1.49M 10-Q · filed 2024-11-06 | $348.00K derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-06-30 | $261.00K 10-Q · filed 2024-08-02 | -$73.00K 10-Q · filed 2024-08-02 | $1.77M derived: sum of 3 quarters · filed 2025-02-19 | $141.00K derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-03-31 | -$334.00K 10-Q · filed 2024-05-03 | $1.51M derived: sum of 2 quarters · filed 2025-02-19 | -$120.00K derived: sum of 3 quarters · filed 2025-02-19 | -$10.30M derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | $1.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $214.00K derived: sum of 2 quarters · filed 2025-02-19 | -$9.97M derived: sum of 3 quarters · filed 2025-02-19 | -$19.30M 10-K · filed 2025-02-19 |
| 2022-09-30 | -$1.63M 10-Q · filed 2023-11-03 | -$11.81M derived: sum of 2 quarters · filed 2023-11-03 | -$21.14M 10-Q · filed 2023-11-03 | -$37.24M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | -$10.18M 10-Q · filed 2023-08-04 | -$19.51M 10-Q · filed 2023-08-04 | -$35.61M derived: sum of 3 quarters · filed 2024-02-21 | -$9.91M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | -$9.33M 10-Q · filed 2023-05-05 | -$25.43M derived: sum of 2 quarters · filed 2024-02-21 | $273.00K derived: sum of 3 quarters · filed 2024-02-21 | -$30.77M derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | -$16.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $9.60M derived: sum of 2 quarters · filed 2024-02-21 | -$21.44M derived: sum of 3 quarters · filed 2024-02-21 | -$42.06M 10-K · filed 2024-02-21 |
| 2021-09-30 | $25.70M 10-Q · filed 2022-11-03 | -$5.34M derived: sum of 2 quarters · filed 2022-11-03 | -$25.96M 10-Q · filed 2022-11-03 | $53.09M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$31.05M 10-Q · filed 2022-07-29 | -$51.66M 10-Q · filed 2022-07-29 | $27.39M derived: sum of 3 quarters · filed 2022-07-29 | $15.87M derived: sum of 4 quarters · filed 2022-07-29 |
| 2021-03-31 | -$20.62M 10-Q · filed 2022-05-06 | $58.44M derived: sum of 2 quarters · filed 2022-05-06 | $46.92M derived: sum of 3 quarters · filed 2022-05-06 | $142.12M derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-12-31 | $79.06M 10-K · filed 2021-02-12 | $67.53M derived: sum of 2 quarters · filed 2021-11-03 | $162.74M derived: sum of 3 quarters · filed 2021-11-03 | $170.40M 10-K · filed 2023-02-17 |
| 2020-09-30 | -$11.52M 10-Q · filed 2021-11-03 | $83.68M derived: sum of 2 quarters · filed 2021-11-03 | $91.35M 10-Q · filed 2021-11-03 | $92.77M derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | $95.20M 10-Q · filed 2021-08-03 | $102.87M 10-Q · filed 2021-08-03 | $104.29M derived: sum of 3 quarters · filed 2021-08-03 | $106.45M derived: sum of 4 quarters · filed 2021-08-03 |
| 2020-03-31 | $7.67M 10-Q · filed 2021-05-05 | $9.09M derived: sum of 2 quarters · filed 2021-05-05 | $11.25M derived: sum of 3 quarters · filed 2021-05-05 | $21.08M derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | $1.42M 10-K · filed 2021-02-12 | $3.58M derived: sum of 2 quarters · filed 2021-02-12 | $13.41M derived: sum of 3 quarters · filed 2021-02-12 | $13.41M 10-K · filed 2022-02-15 |
| 2019-09-30 | $2.17M 10-K · filed 2021-02-12 | $11.99M derived: sum of 2 quarters · filed 2021-02-12 | $11.99M 10-Q · filed 2020-10-27 | |
| 2019-06-30 | $9.83M 10-K · filed 2021-02-12 | $9.83M 10-Q · filed 2020-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |